Vivimed Labs Limited

Vivimed Labs Limited

Vivimed Labs Limited has submitted its audited financial results for the quarter and year ended March 31, 2026, despite being under corporate insolvency resolution process (CIRP) since April 15, 2026. The company has incurred losses and eroded its net worth, but management believes it will continue operations and meet its obligations based on ongoing business plans, promoter support, and expected improvements in operational performance.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange regarding 'COC meeting' for the 8th meeting of the Committee of Creditors (CoC) scheduled to be held on September 29, 2026, through Audio-Visual Means.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange about General Updates, where the Committee of Creditors has approved the filing of an application to the Registrar of Companies seeking an extension of time for convening the AGM for the Financial Year 2025-26.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange about the upcoming 7th meeting of the Committee of Creditors (CoC) under the Corporate Insolvency Resolution Process (CIRP) scheduled to be held on September 10, 2026.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process and scheduled the 6th meeting of the Committee of Creditors on August 18, 2026.

Vivimed Labs Limited

Vivimed Labs Limited has been asked by the Exchange to clarify its financial results for the quarter ended 31-Dec-2025, specifically regarding Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company has not yet responded to the query.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange regarding the re-lodgement of transfer requests of physical shares as per SEBI Circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated 30th January, 2026.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange about General Updates, specifically regarding the newspaper publication of financial results for the quarter and year ended March 31, 2026.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with Regulation 74(5) for the quarter ended 30 June, 2026.

Vivimed Labs Limited

Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from 01.07.2026 till 48 hours after the declaration of the Financial Results for the quarter ended June 30, 2026.

Vivimed Labs Limited

Vivimed Labs Limited has responded to the National Stock Exchange's (NSE) clarification request regarding its financial results for the quarter ended March 31, 2025. The company clarified that the financial results were not submitted in the prescribed format, and there were technical issues with scanning and filing the documents, resulting in a delay in uploading the results.